Weekly Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings on May 17, 2018

May 17, 2018 - By Clyde Turner

Big Money Sentiment decreased to 0.98 in Q4 2017. It has change of 0.31, from 2017Q3’s 1.29. The ratio fall due to Integra LifeSciences Holdings Corporation positioning: 20 sold and 70 reduced. 23 funds acquired stakes and 65 increased stakes. Investors holded 68.21 million in 2017Q3 but now own 70.22 million shares or 2.95% more.
26,418 are held by Bnp Paribas Arbitrage. Blackrock Inc owns 8.14 million shs. Tiaa Cref Invest Limited Com reported 154,451 shs stake. Riverhead Cap Ltd reported 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Massachusetts Financial Services Ma owns 0.01% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 394,988 shs. Raymond James & Associate holds 70,869 shs or 0.01% of its capital. Metropolitan Life Insurance New York accumulated 20,459 shs. Fifth Third Savings Bank reported 0% stake. Conestoga Advsrs Ltd owns 5,000 shs. Regions Financial Corporation stated it has 11,474 shs or 0.01% of all its holdings. State Street owns 1.95M shs for 0.01% of their capital. Ngam Advsr Lp owns 49,192 shs. 9,660 were reported by Parallax Volatility Advisers Lp. Virginia Retirement Systems Et Al stated it has 31,400 shs. Eaton Vance Mgmt holds 131,970 shs.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

In total 9 analysts cover Integra Lifesciences (NASDAQ:IART). “Buy” rating has 3, “Sell” are 0, while 6 are “Hold”. 33% are bullish. 10 are the (NASDAQ:IART)’s analyst reports since January 2, 2018 according to StockzIntelligence Inc. On Thursday, April 26 the firm has “Neutral” rating by JP Morgan given. In Wednesday, April 25 report Jefferies maintained the stock with “Buy” rating. In Thursday, March 29 report Oppenheimer maintained the stock with “Buy” rating. On Wednesday, April 25 the rating was maintained by Cantor Fitzgerald with “Hold”. In Wednesday, April 11 report JP Morgan maintained the stock with “Neutral” rating. On Tuesday, January 2 the company was downgraded by Raymond James. In Wednesday, February 28 report JMP Securities maintained the stock with “Market Outperform” rating. On Tuesday, January 2 the firm has “Neutral” rating by Bank of America given. Listed here are Integra LifeSciences Holdings Corporation (NASDAQ:IART) PTs and latest ratings.

25/04/2018 Broker: Jefferies Rating: Buy New Target: $70.0000 Maintain
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $55 New Target: $57 Maintain
25/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $52.0000 Maintain
11/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $50 New Target: $55 Maintain
05/04/2018 Broker: BTIG Research Rating: Neutral New Target: $56 Initiates Coverage On
29/03/2018 Broker: Oppenheimer Rating: Buy New Target: $58.0000 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $57 New Target: $60 Maintain
08/01/2018 Broker: Barclays Capital Rating: Hold New Target: $53.0
02/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $55 Downgrade
02/01/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade

IART touched $63.85 during the last trading session after $0.66 change.Integra LifeSciences Holdings Corporation is uptrending after having risen 29.35% since May 17, 2017. IART has 666,578 volume or 5.58% up from normal. IART outperformed the S&P 500 by 17.80%.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The firm is worth $5.23 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.The P/E ratio is 77.87. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

A couple more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were released by: Globenewswire.com which released on May 09, 2018 “Integra LifeSciences Prices Public Offering of Common Stock”, also Globenewswire.com on May 09, 2018 released “Integra LifeSciences Announces Proposed Public Offering of Common Stock”, the next Globenewswire.com is “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …” on May 17, 2018. Globenewswire.com has article titled “Integra LifeSciences Reports First Quarter 2018 Financial Results”.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.